文献速递生殖医学

GnRH拮抗剂方案中黄体期与卵泡期启动促排卵后囊胚整倍体率的比较:一项重复促排卵周期的前瞻性研究

Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles.
PubMed 文献 · Hum Reprod · 2022-01-01

44名卵子捐赠者接受两次相同促排卵周期,分别于卵泡期(FS)和黄体期(LS)启动,同一精液样本受精后行胚胎非整倍体筛查。FS与LS的整倍体囊胚数等效(1.59±1.30 vs 1.61±1.17,均值差-0.02,90%CI -0.48;0.44),受精率、囊胚形成率及整倍体率均无显著差异。

要点

  • FS与LS启动的整倍体囊胚数等效,均值差-0.02(90%CI -0.48;0.44)。
  • FS促排卵时间更短(均值差-1.05,95%CI -1.89;-0.20),每日rFSH总剂量更低(均值差-196.02,95%CI -319.92;-72.12)。
  • 受精率、囊胚形成率及整倍体率在FS与LS间无显著差异,分别为71.9% vs 71.4%、59.4% vs 62%、56.9% vs 57.3%。

核心结论

  • 在年轻且可能具有生育力的卵子捐赠者中,黄体期启动促排卵可获得与卵泡期启动相当的卵母细胞数及囊胚整倍体率。

研究设计与样本

  • 前瞻性等效性研究,2018年5月至2021年12月期间,44名卵子捐赠者接受两次相同的连续促排卵周期,一次于卵泡期启动,另一次于黄体期启动。
  • 44名卵子接受者参与研究,每个刺激周期接受平均6个MII卵母细胞,所有MII卵母细胞均使用对应接受者伴侣的精子(预先冷冻)或供精者精子受精。

主要发现

  • FS与LS的促排卵时间均值差为-1.05(95%CI -1.89; -0.20),FS更短。
  • FS与LS的每日rFSH总追加剂量均值差为-196.02(95%CI -319.92; -72.12),FS更低。
  • FS与LS的获卵数分别为23.70±10.79与23.70±8.81,均值差0.00(95%CI -3.03; 3.03);MII卵母细胞数分别为20.27±9.60与20.73±8.65,均值差-0.45(95%CI -2.82; 1.91)。
  • FS与LS的受精率分别为71.9%与71.4%,囊胚形成率分别为59.4%与62%,胚胎整倍体率分别为56.9%与57.3%,均无显著差异。
  • FS与LS的整倍体囊胚数分别为1.59±1.30与1.61±1.17,均值差-0.02(90%CI -0.48; 0.44),等效。

关键数值与推荐

  • 总体囊胚形成率为60.70%,整倍体率为57.1%。

临床怎么用

  • 作者认为,对于卵巢储备良好的年轻患者,在全胚冷冻方案中,临床医生可安全考虑在黄体期启动促排卵。

局限性

  • 研究在年轻、可能具有生育力的卵子捐赠者中进行,这些患者囊胚整倍体率高。
  • 结果可能外推至卵巢储备良好的年轻不孕女性,但在推广至年龄较大的不孕女性前需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there any difference in the mean number of euploid embryos following luteal phase start (LS) and follicular phase start (FS) of ovarian stimulation? SUMMARY ANSWER: The mean number of euploid blastocysts is equivalent independent of whether the inseminated oocytes are derived from FS or LS. WHAT IS KNOWN ALREADY: Starting ovarian stimulation at any time of the cycle ('random-start') is commonly used for emergency fertility preservation in cancer patients. A few retrospective studies have been published evaluating LS in women undergoing ovarian stimulation in the context of IVF, but there is a lack of robust data on the comparative efficacy of LS versus FS.Although 'random start' is commonly used in cancer survivors, few retrospective and uncontrolled studies have been published evaluating luteal phase stimulation in women undergoing ovarian stimulation in the context of IVF. Owing to this evident lack of robust data on the efficacy of LS, guidelines typically recommend the LS approach only for medical reasons and not in the context of IVF. STUDY DESIGN, SIZE, DURATION: This is a prospective, equivalence study, with repeated stimulation cycles, conducted between May 2018 and December 2021. Overall, 44 oocyte donors underwent two identical consecutive ovarian stimulation cycles, one initiated in the FS and the other in the LS. The primary outcome of the study was to evaluate whether FS and LS in the same patient would result in equivalent numbers of euploid embryos following fertilization of oocytes with the same sperm sample. PARTICIPANTS/MATERIALS, SETTING, METHODS: Overall, 44 oocyte donors underwent two consecutive ovarian stimulation protocols with 150 μg corifollitropin alpha followed by 200 IU recombinant FSH (rFSH) in a fixed GnRH antagonist protocol. The only difference between the two cycles was the day of initiation of ovarian stimulation, which was in the early follicular phase (FS) in one cycle, and in the luteal phase (LS) in the other. Forty-four oocyte recipients participated in the study receiving a mean of six metaphase II (MII) oocytes from each stimulation cycle (FS and LS). All MIIs were inseminated with the corresponding recipient's partner sperm (which had been previously frozen) or donor sperm, in order to safeguard the use of the same sample for either the FS or LS. Following fertilization and blastocyst culture, all generated embryos underwent genetic analysis for aneuploidy screening (preimplantation genetic testing for aneuploidy). MAIN RESULTS AND THE ROLE OF CHANCE: FS resulted in a significantly shorter duration of ovarian stimulation (difference between means (DBM) -1.05 (95% CI -1.89; -0.20)) and a lower total additional dose of daily rFSH was needed (DBM -196.02 (95% CI -319.92; -72.12)) compared with LS. The donors' hormonal profile on the day of trigger was comparable between the two stimulation cycles, as well as the mean number of oocytes (23.70 ± 10.79 versus 23.70 ± 8.81) (DBM 0.00 (95% CI -3.03; 3.03)) and MII oocytes (20.27 ± 9.60 versus 20.73 ± 8.65) (DBM -0.45 (95% CI -2.82; 1.91)) between FS and LS cycles, respectively. Following fertilization, the overall blastocyst formation rate was 60.70% with a euploid rate of 57.1%. Comparisons between the two stimulation cycles did not reveal any significance differences in terms of fertilization rates (71.9% versus 71.4%), blastocyst formation rates (59.4% versus 62%) and embryo euploidy rates (56.9 versus 57.3%) for the comparison of FS versus LS, respectively. The mean number of euploid blastocysts was equivalent between the FS (1.59 ± 1.30) and the LS (1.61 ± 1.17), (DBM -0.02 (90%CI -0.48; 0.44)). LIMITATIONS, REASONS FOR CAUTION: The study was performed in young, potentially fertile oocyte donors who are patients with high blastocyst euploidy rates. Although results may be extrapolated to young infertile women with good ovarian reserve, caution is needed prior to generalizing the results to infertile women of older age. WIDER IMPLICATIONS OF THE FINDINGS: The current study provides evidence that initiation of ovarian stimulation in the luteal phase in young potentially fertile women may result in a comparable number of oocytes and comparable blastocyst euploidy rates compared with follicular phase stimulation. This may imply that in case of a freeze-all protocol in young patients with good ovarian reserve, clinicians may safely consider initiation of ovarian stimulation during the luteal phase. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by an unrestricted grant from MSD/Organon. N.P.P. has received Research grants and honoraria for lectures from: Merck Serono, MSD/Organon, Ferring Pharmaceuticals, Besins Intenational, Roche Diagnostics, IBSA, Theramex, Gedeon Richter. F.M., E.C., M.R. and S.G. declared no conflict of interests. TRIAL REGISTRATION NUMBER: The study was registered at Clinical Trials Gov (NCT03555942).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Martinez F, Clua E, Roca M, et al. Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles. Hum Reprod. 2022. PMID: 36269092. doi:10.1093/humrep/deac222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。